Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged postoperative low-molecular-weight heparin prophylaxis after abdominal or pelvic cancer surgery
ChiCTR2000036497Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of low molecular weight heparin calcium in venous thromboembolism (VTE) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: VTE occurrence at postoperative week 4, VTE occurrence at postoperative week 8 and 4 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR2000036497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036497.